Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Get the latest international news and world events from around the world.

Log in for authorized contributors

New insights on CRISPR/Cas9based therapy for breast Cancer Environment

CRISPR/Cas9 has revolutionized genome-editing techniques in various biological fields including human cancer research. Cancer is a multi-step process that encompasses the accumulation of mutations that result in the hallmark of the malignant state. The goal of cancer research is to identify these mutations and correlate them with the underlying tumorigenic process. Using CRISPR/Cas9 tool, specific mutations responsible for cancer initiation and/or progression could be corrected at least in animal models as a first step towards translational applications. In the present article, we review various novel strategies that employed CRISPR/Cas9 to treat breast cancer in both in vitro and in vivo systems.

Breast tissue regeneration is driven by cellmatrix interactions coordinating multilineage stem cell differentiation through DDR1 Communications

Breast tissue regeneration is driven by cell-matrix interactions coordinating multi-lineage stem cell differentiation through DDR1.

Mammary morphogenesis is a complex process. Here the authors describe how stem cells build a three-dimensional self-organizing multi-lineage tissue by showing that positional signals from the extracellular matrix through the collagen receptor DDR1 lead stem cells to differentiate into multi-lineage committed multi-layered progeny.

3D-printed tissue restores erectile function and aids reproduction in animal study

Erectile dysfunction affects over 40% of men over 40, yet our understanding of the condition remains limited. Research on this issue has mostly relied on real organs, making it difficult to study the detailed interaction between blood flow and tissue during an erection.

In a recent study published in Nature Biomedical Engineering, a team of scientists from China, Japan and the U.S. presented a 3D printed hydrogel-based penile model complete with essential blood vessels to mimic the natural function of a penis.

Once implanted into rabbits and pigs with penile deformities, the bioengineered organ enabled them to mate and reproduce within weeks.

3Dprinted perfused models of the penis for the study of penile physiology and for restoring erectile function in rabbits and pigs Biomedical Engineering

3D-printed models of the penis can facilitate the study of penile physiology and the repair of penile defects, as shown via a reconstructed and implanted corpus cavernosum that restored erectile function and mating capacity in rabbits and pigs.

Chinaled team uses 3Dprinted male sex organ for ED treatment in world first

ED affects more than 40 per cent of men aged 40 and above. The team of researchers used hydrogel-based bioinks to develop a 3D-printed penile implant system able to anatomically replicate all functional components of natural erectile tissue.

The animal subjects – pigs and rabbits – exhibited restored erectile capacity post-implantation, with reproductive success rates surging from 25 per cent in the control group to 100 per cent in the treatment group, the team said.

Details of the landmark study were published in Nature Biomedical Engineering on March 4.

UBC scientists discover how to 3D print testicular cells

In a pair of world firsts, UBC scientists have 3D printed human testicular cells and identified promising early signs of sperm-producing capabilities.

The researchers, led by UBC urology assistant professor Dr. Ryan Flannigan, hope the technique will one day offer a solution for people living with presently untreatable forms of male infertility.

“Infertility affects 15 per cent of couples and male factors are a contributing cause in at least half those cases,” said Dr. Flannigan, whose lab is based at the Vancouver Prostate Centre at Vancouver General Hospital.

Strengthening muscle for healthy ageing: innovative treatments for sarcopenia

There are currently no approved therapies for sarcopenia, the age-related loss of skeletal muscle mass and strength. This Review discusses advances in understanding of the cellular, molecular and metabolic mechanisms driving muscle wasting with ageing, while assessing emerging therapeutic approaches and agents in development.

Treatment strategies and innovation for recurrent highgrade glioma NeuroOncology

Recurrent high‑grade glioma (HGG)—including glioblastoma—remains lethal, with median survival of approximately 6–10 months after first progression, although patients with IDH mutant tumors often have better survival. Recent ASCO/SNO data and expanding trial data are reshaping available treatment strategies.

We review evidence for alkylators and anti‑angiogenic therapy; summarize targeted options for rare, actionable alterations; review immuno‑oncology combinations and cellular therapies; highlight DNA damage response (DDR)/radiosensitization strategies and discuss advances in blood–brain barrier modulation and locoregional delivery. We propose a patient‑centered algorithm that prioritizes trial enrollment, biomarker‑guided approaches, steroid stewardship, and quality of life.

Lomustine, temozolomide rechallenge, and bevacizumab remain commonly used but provide modest benefit. Targeted agents show meaningful activity only in select subsets (BRAF V600E, NTRK). DDR-directed agents such as ATM/ATR inhibitors show early promise. Immunotherapy advances center on rationale combinations, oncolytic viruses, and locoregionally delivered CAR-T/TCR platforms. Blood-Brain-Barrier (BBB) modulation strategies and adaptive trials are broadening access to innovative therapies. The 2025 landscape features meaningful, if incremental, options—alongside the first ever FDA‑approved therapy for H3K27M‑mutant diffuse midline glioma at relapse—and a pipeline of rational combinatorial approaches poised to refine outcomes for selected patients. This article concentrates on medical options and intentionally omits extended discussions of surgery and radiation beyond their integration with systemic therapies at recurrence.

Distal Vessel Occlusions in Acute Ischemic StrokeReframing Patient Selection and Reperfusion Strategies

Mechanical thrombectomy (MT) has revolutionized the treatment of acute ischemic stroke because of large vessel occlusion (LVO), but distal and medium vessel occlusions (DMVOs) remain a gray zone. DMVOs account for a substantial proportion of ischemic strokes and can cause long-term disability or death despite often presenting with only mild to moderate symptoms. Their biologic and anatomic diversity—including small vessel caliber, variable perfusion territories, collateral dependence, and complex access pathways—creates distinct patterns of natural history, treatment responsiveness, and procedural risk compared with proximal LVO.

/* */